Jobs at risk in Germany due to Sanofi’s Toujeo performance

Sanofi reported last week its 2016 financial results, together with the performance by Toujeo, the insulin expected to replace the blockbuster Lantus, which has recently lost its patent protection. Toujeo is pivotal for Sanofi’s German branch, which has hired 500 new employees in order to launch the drug, but half of them with a temporary contract. German daily Frankfurter Rundschau reported that the the staff trade union IG BCE has recently learned that temporary contracts will not be extended. Sanofi employs 9,200 staff in Germany, 7,300 of which in Frankfurt and 1,100 in Berlin.
(Source Frankfurter Rundschau)